公开(公告)号：US20210380609A1

公开(公告)日：2021-12-09

申请号：US17401892

申请日：2021-08-13

Applicant: Loxo Oncology, Inc. ,  Array BioPharma Inc.

Inventor： Charles Todd EARY ,  Stacey SPENCER ,  Zack CRANE ,  Katelyn CHANDO ,  Sylvie ASSELIN ,  Weidong LIU ,  Mike WELCH ,  Adam COOK ,  Gabrielle R. KOLAKOWSKI ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG

IPC: C07D519/00 ,  C07D471/04

Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

公开(公告)号：US20220112214A1

公开(公告)日：2022-04-14

申请号：US17274990

申请日：2019-09-06

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Dean KAHN ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Andrew T. METCALF ,  David A. MORENO ,  Brett PRIGARO ,  Ginelle A. RAMANN ,  Li REN ,  Shane M. WALLS ,  Hailong ZHANG

IPC: C07D498/22 ,  C07D513/22 ,  C07D498/14 ,  A61K45/06 ,  A61K31/554 ,  A61K31/55 ,  A61K31/519 ,  C07D487/14 ,  A61P35/00

Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20200308194A1

公开(公告)日：2020-10-01

申请号：US16902424

申请日：2020-06-16

Applicant: Loxo Oncology, Inc. ,  Array BioPharma Inc.

Inventor： Charles Todd EARY ,  Stacey SPENCER ,  Zack CRANE ,  Katelyn CHANDO ,  Sylvie ASSELIN ,  Weidong LIU ,  Mike WELCH ,  Adam COOK ,  Gabrielle R. KOLAKOWSKI ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG

IPC: C07D519/00 ,  C07D471/04

Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

公开(公告)号：US20220081438A1

公开(公告)日：2022-03-17

申请号：US17416117

申请日：2019-12-13

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. Blake ,  David A. MORENO ,  Li REN ,  Tony P. TANG ,  Shane M. WALLS

IPC: C07D471/04 ,  C07D519/00

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

公开(公告)号：US20200339579A1

公开(公告)日：2020-10-29

申请号：US16962305

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： Shane M. WALLS ,  LI REN ,  Ginelle A. RAMANN ,  David A. MORENO ,  Andrew T. METCALF ,  Elizabeth A. MCFADDIN ,  Gabrielle R. KOLAKOWSKI ,  James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Dean KAHN

IPC: C07D471/04 ,  C07F9/6561

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220313676A1

公开(公告)日：2022-10-06

申请号：US17108528

申请日：2020-12-01

Applicant: Array Biopharma Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  James COLLIER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Ginelle A. RAMANN ,  Tony P. TANG ,  Li REN ,  Shane M. WALLS

IPC: A61K31/4545 ,  A61K31/4162 ,  C07D471/04 ,  A61P1/00 ,  A61P35/00 ,  A61P35/02 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P1/12

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20200339589A1

公开(公告)日：2020-10-29

申请号：US16962345

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Andrew T. METCALF ,  David A. MORENO ,  Brett PRIGARO ,  Ginelle A. RAMANN ,  Li REN

IPC: C07D487/04

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20240066029A1

公开(公告)日：2024-02-29

申请号：US18342314

申请日：2023-06-27

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. Blake ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

CPC classification number: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20230090520A1

公开(公告)日：2023-03-23

申请号：US17530702

申请日：2021-11-19

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220119396A1

公开(公告)日：2022-04-21

申请号：US17514684

申请日：2021-10-29

Applicant: Array BioPharma Inc.

Inventor： Steven W. ANDREWS ,  James F. BLAKE ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  David A. MORENO ,  Li REN ,  Shane M. WALLS

IPC: C07D487/04

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.